Author: NeLM - Ophthalmology

Change to injection needle supplied with ranibizumab (Lucentis®)

Source: Personal communication (Novartis)
Area: News
Novartis Pharmaceuticals UK Limited is advising customers of a forthcoming change to the injection needle supplied in packs of ranibizumab (Lucentis®). 
The needle supplier is being switched from Becton & Dickinson to B.Braun at the end of December 2012. Customers may therefore notice a difference in the appearance of the injection needle and the outer packaging of the needle. Novartis has stressed that the rest of the pack will remain the same, including the filter needle.

Horizon scanning: Aflibercept (EYLEA) filed for approval in EU for treatment of macular oedema following central retinal vein occlusion

Source: PharmaLive
Area: News
Bayer HealthCare has submitted an application for marketing authorisation in the EU for aflibercept (EYLEA) injection for the treatment of macular oedema following central retinal vein occlusion.
The submission is based on data from the phase III COPERNICUS and GALILEO studies which had as the primary efficacy endpoint, the proportion of patients who gained at least 15 ETDRS letters of Best Corrected Visual Acuity (BCVA) at 24 weeks compared to baseline on the ETDRS visual acuity charts. The aflibercept 2mg monthly group was reported to (Read more...)